Haploid Allogeneic Transplant Using the CliniMACS System
Stopped early · Phase 2
Conditions studied: Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase, Myelodysplastic Syndrome (MDS) - High and Intermediate Risk, Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) - Refractory
In brief
To assess the proportion of patients with donor neutrophil engraftment within 30 days of allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after transplantation.
Key facts
- Study ID
- NCT00185679
- Run by
- Ginna Laport
- People needed
- 13
- Starts
- 2001-11-01
- Expected to finish
- 2010-02-01
- Last updated by the study team
- 2015-03-09
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.